Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01

BACKGROUND: The development of an asexual blood stage vaccine against Plasmodium falciparum malaria based on the major merozoite surface protein-1 (MSP1) antigen is founded on the protective efficacy observed in preclinical studies and induction of invasion and growth inhibitory antibody responses....

Descripción completa

Detalles Bibliográficos
Autores principales: Otsyula, Nekoye, Angov, Evelina, Bergmann-Leitner, Elke, Koech, Margaret, Khan, Farhat, Bennett, Jason, Otieno, Lucas, Cummings, James, Andagalu, Ben, Tosh, Donna, Waitumbi, John, Richie, Nancy, Shi, Meng, Miller, Lori, Otieno, Walter, Otieno, Godfrey Allan, Ware, Lisa, House, Brent, Godeaux, Olivier, Dubois, Marie-Claude, Ogutu, Bernhards, Ballou, W Ripley, Soisson, Lorraine, Diggs, Carter, Cohen, Joe, Polhemus, Mark, Heppner, D Gray, Ockenhouse, Christian F, Spring, Michele D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582548/
https://www.ncbi.nlm.nih.gov/pubmed/23342996
http://dx.doi.org/10.1186/1475-2875-12-29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582548/
https://www.ncbi.nlm.nih.gov/pubmed/23342996
http://dx.doi.org/10.1186/1475-2875-12-29

Ejemplares similares